XORTX Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XRTX Nasdaq 2836 www.xortx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for XORTX Therapeutics Inc.

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - Jun 12th, 2026 3:00 pm
XORTX Announces Closing of US$5 Million Public Offering - May 19th, 2026 5:00 am
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - May 18th, 2026 9:20 am
XORTX Announces US$5 Million Public Offering - May 14th, 2026 5:00 am
XORTX Meets Nasdaq Continued Listing Requirements - Apr 21st, 2026 5:00 am
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset - Apr 13th, 2026 3:00 pm
XORTX Confirms Effective Date of Share Consolidation - Apr 1st, 2026 11:00 am
XORTX Announces Results of Annual and Special Meeting of Shareholders - Mar 26th, 2026 4:00 pm
XORTX Announces Change of Effective Date of Share Consolidation - Mar 26th, 2026 2:32 pm
XORTX Announces Share Consolidation - Mar 25th, 2026 4:15 pm
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting - Mar 24th, 2026 3:00 pm
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders - Mar 18th, 2026 5:00 am
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation - Mar 13th, 2026 5:00 am
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - Mar 5th, 2026 5:00 am
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - Feb 4th, 2026 4:00 pm
XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment - Jan 2nd, 2026 5:24 am
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update - Dec 31st, 2025 4:15 pm
XORTX Announces Closing of US$1.1 Million Registered Direct Offering - Oct 29th, 2025 5:00 am
XORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering - Oct 21st, 2025 6:13 am
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering - Oct 21st, 2025 6:00 am